Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Best Pract Res Clin Haematol ; 18(2): 277-87, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15737890

RESUMEN

Labile plasma iron (LPI) represents a component of non-transferrin-bound iron (NTBI) that is both redox-active and chelatable, capable of permeating into organs and inducing tissue iron overload. It appears in various types of hemosiderosis (transfusional and non-transfusional) and in other iron-overload conditions. Sustained levels of LPI could over time compromise organ (e.g. heart) function and patient survival. With the advent of methods for measuring LPI in the clinical setting, it has become possible to assess the implications of LPI in the management of iron overload based on regimens of iron chelation. As LPI is detected primarily in patients with transfusional iron overload and other forms of hemosiderosis, we review here regimens of iron chelation with deferrioxamine and deferiprone (separately or combined) in terms of their efficacy in minimizing daily exposure to LPI in thalassemia major and thalassemia intermedia patients.


Asunto(s)
Sobrecarga de Hierro/metabolismo , Hierro/sangre , Talasemia/sangre , Deferiprona , Humanos , Hierro/metabolismo , Quelantes del Hierro/metabolismo , Quelantes del Hierro/uso terapéutico , Oxidación-Reducción , Piridonas/uso terapéutico , Talasemia/tratamiento farmacológico , Talasemia/etiología , Talasemia beta/sangre , Talasemia beta/tratamiento farmacológico
2.
J Clin Pathol ; 32(9): 912-7, 1979 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-315966

RESUMEN

alpha-naphthyl acetate esterase (ANAE) activity has been investigated in leukaemic cells from peripheral blood in a typical small-cell Sézary syndrome (SS) case in which cerebriform mononuclear cells failed to form E rosettes. The 'dot-like' ANAE positivity found in the majority of these neoplastic cells strongly supports a T-cell origin. In addition, a non-monocytic, non-B-cell nature of Sézary cells is indicated by the lack of Ia-like antigens. Finally, there is evidence of a distinct portion of Sézary cells simultaneously expressing ANAE activity and Fc IgM receptors.


Asunto(s)
Síndrome de Sézary/sangre , Linfocitos T , Esterasas/sangre , Humanos , Masculino , Microscopía Electrónica , Persona de Mediana Edad , Naftoles , Receptores Fc/aislamiento & purificación , Formación de Roseta , Síndrome de Sézary/enzimología , Síndrome de Sézary/inmunología , Linfocitos T/enzimología , Linfocitos T/inmunología , Linfocitos T/ultraestructura
3.
Ann Ital Med Int ; 7(3): 137-40, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-1457252

RESUMEN

We carried out total body computerized tomography (CT) studies and examined the retrospective clinical data of 29 adult patients with thalassemia intermedia (TI) to evaluate the incidence, features and pathogenesis of ectopic erythropoiesis (EE), located chiefly at the paravertebral gutters in the thorax, was present in 65.5% of the patients; 15% of them had severe clinical complications. We found a clear relationship between EE development and early presentation age of thalassemia, splenectomy and the presence of 100% fetal hemoglobin. The frequent occurrence of EE suggests that CT screening of patients with thalassemia intermedia should be mandatory. We also recommend radiotherapy as a preventive measure for the clinical complications of thalassemic patients with EE.


Asunto(s)
Eritropoyesis , Hematopoyesis Extramedular , Talasemia/epidemiología , Adolescente , Adulto , Estudios de Seguimiento , Humanos , Incidencia , Italia/epidemiología , Persona de Mediana Edad , Estudios Retrospectivos , Talasemia/sangre
6.
J Neurol Neurosurg Psychiatry ; 76(12): 1717-9, 2005 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-16291901

RESUMEN

BACKGROUND: Episodic non-ketotic hyperglycaemia in patients with diabetes may be responsible for a syndrome characterised by hemichorea-hemiballism associated with unique radiological features. OBJECTIVE: To investigate whether factors other than hyperglycaemia may be responsible for the neurological involvement. METHODS: Three patients who developed a persistent chorea-ballism syndrome triggered by a hyperglycaemic crisis were investigated. In these patients, the persistence of the involuntary movements required neuroleptic medication. RESULTS: T1 weighted magnetic resonance imaging revealed bilateral hyperintense lesions involving the striatum. Surprisingly, in these patients, the laboratory investigations revealed peripheral red blood cell acanthocytosis in a significant proportion of cells. CONCLUSION: Compared with the large population of patients with diabetes who do not show abnormal involuntary movements, unrecognised acanthocytosis in diabetes might render patients prone to develop hemichorea-hemiballism.


Asunto(s)
Corea/etiología , Discinesias/etiología , Eritrocitos/patología , Hiperglucemia/complicaciones , Hiperglucemia/etiología , Anciano , Anciano de 80 o más Años , Complicaciones de la Diabetes , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Síndrome
7.
Ann Hematol ; 73(6): 279-81, 1996 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9003157

RESUMEN

In some patients compliance to subcutaneous desferrioxamine therapy is reduced because of allergic symptoms. Effective drug desensitization consists of bringing patients to tolerate the same mode of administration. We evaluated three thalassemic patients with severe allergies to desferrioxamine. Each patient received weekly three prefilled infusors with desferrioxamine 4 g/48 m1/48 h for s.c. therapy. Follow-up was performed for 12 consecutive weeks. During follow-up no allergic events were noted. The s-ferritin levels decreased from 2583 micrograms/l +/- 485 to 1916 micrograms/l +/- 275 (mean decrease 25.8%, p = 0.038). Compliance to the infusional system was excellent. Our results show that continuous infusion of desferrioxamine using a new infusional delivery system is effective in preventing allergic reactions and in reducing iron overload.


Asunto(s)
Deferoxamina/administración & dosificación , Hipersensibilidad a las Drogas/prevención & control , Hemocromatosis/inmunología , Adulto , Biopsia , Degranulación de la Célula , Quelantes/uso terapéutico , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Inyecciones Subcutáneas , Cooperación del Paciente , Piel/patología
8.
Haematologica ; 83(6): 525-32, 1998 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-9676026

RESUMEN

BACKGROUND AND OBJECTIVE: After the first National Census of transfusion-dependent thalassemics (1984), in 1992 the Italian Association of Pediatric Hematology and Oncology and the National Health Institute organized its 3rd edition. Here, results concerning Latium are presented and discussed. DESIGN AND METHODS: Data for Latium, as in the rest of Italy, were collected by a single reference center; among all eventual care centers for thalassemia initially contacted, only those with patients were sent data forms. For new cases, a questionnaire was submitted to parents to obtaining social data, and information on their knowledge of thalassemia. RESULTS: Collected data were divided into 2 groups: old cases, before June 30, 1988, and new cases, between July 1, 1988 and December 31, 1992. On the whole, 262 transfusion-dependent thalassemics (127 m., 135 f.) could be counted. Sixteen percent were affected with thalassemia intermedia, severe enough as to need regular transfusions. New patients (last 5 years): the birth of almost 80% of them was due to combined mistakes of parents and doctors. Disease evolution: 19/262 patients had been submitted to BMT (presently transfusion-free). Causes of death: 22 patients died in the considered period, mostly for cardiologic complications. INTERPRETATION AND CONCLUSIONS: Data emerging from censuses on specific pathologies of high social impact (such as thalassemia) may help health plans to rationalize public expenditure, especially by improving working conditions of care centers.


Asunto(s)
Talasemia/epidemiología , Femenino , Humanos , Italia/epidemiología , Masculino , Tamizaje Masivo , Prevalencia , Talasemia/prevención & control
9.
Radiol Med ; 91(6): 764-8, 1996 Jun.
Artículo en Italiano | MEDLINE | ID: mdl-8830363

RESUMEN

Eight transfusion dependent patients (3 women and 5 men) with thalassemia major undergoing long-term treatment with Desferoxamine were submitted to MRI, with T2* GE sequences and low field strength. The ratio between liver mean signal intensity and skeletal muscle (L/M) and the ratio between the former and subcutaneous fat (L/F) were calculated in all patients. The results were compared with those of a control group of 7 healthy volunteers (7 men). L/M and L/F ratios were separately correlated with the following parameters: patient's age, transfusion history, serum ferritin, ferritin peak and its onset, transaminases (AST and ALT) and chelation index. The latter is a complex parameter allowing the actual assessment of iron content and of the real efficacy of chelation therapy. In all patients, both the L/M and the L/F ratios decreased significantly (L/M ratio: 0.67 +/- 0.45 vs. 1.2 +/- 0.21, p < 0.02; L/F ratio: 0.39 +/- 0.15 vs. 0.84 +/- 0.11, p < 0.001) relative to the control group. No significant correlation was found between the ratios and any hematochemical parameter, except for r = 0.77 (p < 0.04) between L/F ratio and the chelation index. Our study demonstrates that MRI may play a major role in the examination of thalassemic patients even at low field strength and with GE sequences, which yield good quality images with a relatively short acquisition time. Thus, MRI can be suggested for routine liver studies thanks to its high quality depiction of the liver and to its qualitative and semiquantitative yield. The good correlation between L/F ratio and the chelation index permits MR evaluation of the efficacy of different chelation treatments.


Asunto(s)
Hierro/metabolismo , Hígado/metabolismo , Hígado/patología , Imagen por Resonancia Magnética , Talasemia beta/metabolismo , Adolescente , Adulto , Femenino , Humanos , Imagen por Resonancia Magnética/métodos , Masculino
10.
Eur J Haematol ; 64(6): 426-9, 2000 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10901597

RESUMEN

Patients with beta-globin disorders show amelioration of clinical condition by sustained synthesis of fetal haemoglobin in adult life. We report data on a patient with beta(o)-thalassaemia genotype and thalassaemia intermedia clinical phenotype. He received therapy with hydroxyurea (20 mg/kg/d) because of the presence of extramedullary masses causing paraparesis, neurogenic bladder and impotence. During therapy, the patient showed an improved clinical picture and a significant increase in total Hb (from 71.8 to 103.2 g/L) and a gamma/alpha globin synthetic ratio (from 0.39 to 0.68). The myelosuppressive effect of hydroxyurea was revealed by a decrease in CFU-GEMM, BFU-E, and CFU-GM. Therefore hydroxyurea can be effective in the treatment of patients with extramedullary haematopoiesis (EMH) who are not transfusion-dependent and cannot be treated with radiotherapy.


Asunto(s)
Hematopoyesis Extramedular , Hidroxiurea/uso terapéutico , Paraparesia/tratamiento farmacológico , Polirradiculopatía/tratamiento farmacológico , Talasemia beta/complicaciones , Adulto , Humanos , Italia , Masculino , Paraparesia/etiología , Polirradiculopatía/etiología , Resultado del Tratamiento
11.
Ann Hematol ; 67(4): 183-6, 1993 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-8218539

RESUMEN

Serum concentrations of erythropoietin (EPO) were determined by immunoassay in 45 patients with thalassemia intermedia (TI). The mean serum level of EPO was significantly higher in the thalassemic patients than in the controls, but transfused subjects had lower pretransfusional serum concentrations of EPO than untransfused ones. An inverse relationship between the serum values of EPO and total hemoglobin was observed only in the untransfused thalassemic patients. These data suggest that in TI, even a low transfusional regimen may cause a decrease in serum concentration of EPO, independent of the level of total Hb.


Asunto(s)
Eritropoyetina/sangre , Talasemia/sangre , Adolescente , Adulto , Transfusión Sanguínea , Eritroblastos/citología , Femenino , Ferritinas/sangre , Humanos , Masculino , Persona de Mediana Edad , Talasemia/terapia
12.
Radiol Med ; 85(5): 570-3, 1993 May.
Artículo en Italiano | MEDLINE | ID: mdl-8327757

RESUMEN

Fifteen thalassemia intermedia patients were considered, whose clinical and radiological findings were examined and compared. Eight patients underwent regular transfusion therapy. All patients underwent total body CT: the volume of ectopic erythropoiesis foci was calculated by a digital calculation algorithm (ROI volume). This work was aimed at correlating the quantitative measures of ectopic erythropoiesis assessed by CT with serum level of erythropoietin (EPO) and of trasferrin-free receptors (TfR) in both transfused and non-transfused patients, also considering the volume changes of ectopic erythropoiesis and bone changes over 36 months' follow-up. A direct correlation was demonstrated between serum transferrin and ectopic erythropoietic masses in transfusion-dependent patients: in fact, increased values of serum transferrin correspond to the enlargement of these masses and to bone lesion worsening.


Asunto(s)
Hematopoyesis Extramedular , Tomografía Computarizada por Rayos X , Talasemia beta/diagnóstico por imagen , Adolescente , Adulto , Niño , Eritropoyetina/sangre , Femenino , Humanos , Masculino , Receptores de Transferrina/análisis , Talasemia beta/sangre , Talasemia beta/fisiopatología
13.
Eur J Clin Invest ; 32(9): 700-6, 2002 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-12486871

RESUMEN

BACKGROUND: Congenital haemolytic anaemia may be associated with pseudoxanthoma elasticum (PXE)-like clinical manifestations. METHODS: The cardiovascular system of 14 homozygous and double heterozygous beta-thalassaemia patients with skin and retinal vessel alterations similar to those in genetic PXE was analysed over a period of 12 years and compared with that of 13 relatives (five sets of parents, one single parent, two thalassaemic brothers), and that of the control group composed of 16, age- and sex-matched, thalassaemic patients. RESULTS: All patients with clinical PXE-like skin lesions exhibited, by light and electron microscopy, dermal alterations and mineralization of elastic fibres identical to those typical of inherited PXE. None of the relatives and none of the control group showed clinical or structural findings of PXE. The follow-up started in 1988. After 12 years of clinical observation, six patients showed dramatic progression of skin involvement, angioid streaks had progressed in two subjects. One patient had recurrent gastrointestinal bleeding and underwent partial stomach removal for gastric artery aneurysm, one underwent colon resection for intestinal infarct, one patient had a transitory ischaemic attack, one died after an intracranial haemorrhage, two patients died from cardiovascular disease and one from neoplasia. CONCLUSIONS: Thalassaemic patients with PXE-like skin lesions also manifest PXE-like vessel alterations that progress with time. Considering the severe outcome of these lesions, accurate monitoring should be routinely performed on the cardiovascular system of thalassaemic patients with PXE-like skin manifestations.


Asunto(s)
Enfermedades Cardiovasculares/patología , Tejido Elástico/patología , Talasemia beta/patología , Adolescente , Adulto , Estrías Angioides/patología , Estudios de Casos y Controles , Niño , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Heterocigoto , Homocigoto , Humanos , Masculino , Persona de Mediana Edad , Seudoxantoma Elástico/patología
14.
Br J Haematol ; 84(1): 111-7, 1993 May.
Artículo en Inglés | MEDLINE | ID: mdl-7687856

RESUMEN

Thromboembolic events, which are associated with significant morbidity and mortality, occur in beta-thalassaemia. We studied the expression of the platelet selectin PADGEM/GMP-140 on intact cells from thalassaemic patients, as a marker of in vivo platelet activation. The mean of positive cells (%) was 38.143 +/- 20.65 in the patients versus 5.048 +/- 1.8 in the controls, n = 21, P < 0.001. No correlation was found between GMP-140 expression and splenectomy, platelet counts, plasma ferritin and natural coagulation inhibitors. Instead an indirect correlation was found between GMP-140 expression and HDL-cholesterol. Moreover platelet activation was directly correlated with pre-beta lipoproteins. Our data indicate that thalassaemic patients present an in vivo platelet activation, which possibly depends on the dyslipidaemia, which is now regarded as a frequent feature of this disease.


Asunto(s)
Plaquetas/química , Activación Plaquetaria/fisiología , Glicoproteínas de Membrana Plaquetaria/análisis , Talasemia beta/sangre , Adolescente , Adulto , Niño , Colesterol/sangre , HDL-Colesterol/sangre , Femenino , Homocigoto , Humanos , Lipoproteínas VLDL/sangre , Masculino , Selectina-P
15.
Ann Hematol ; 72(6): 379-81, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8767108

RESUMEN

We report a patient with thalassemia intermedia who developed a mediastinal syndrome due to the growth of paravertebral hematopoietic masses in the posterior mediastinum. Because the patient did not receive blood transfusions due to alloimmunization, she was first treated with human recombinant erythropoietin (escalating low-moderate doses) to recover hemoglobin levels, then in association with radiotherapy to prevent a worsening of her anemia. The mean Hb level dramatically increased and peaked at week 11, to 83 g/l, and remained unchanged before and after radiotherapy (81 versus 78 g/l). Immediately after radiotherapy extramedullary hematopoiesis volume decreased by 16.4%.


Asunto(s)
Eritropoyetina/uso terapéutico , Hematopoyesis Extramedular/efectos de la radiación , Isoanticuerpos/análisis , Talasemia/fisiopatología , Talasemia/terapia , Adulto , Femenino , Humanos , Radioterapia , Proteínas Recombinantes , Talasemia/radioterapia
16.
Haematologica ; 77(6): 514-5, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-1289188

RESUMEN

A patient with transfusion-dependent thalassemia was undergoing home intravenous desferrioxamine (DFX) treatment by means of a totally implanted system because of his poor compliance with the nightly subcutaneous therapy. Due to an accidental malfunctioning of the infusion pump, the patient was inadvertently administered a toxic dosage of the drug which caused renal insufficiency. Given the progressive deterioration of the symptoms and of the laboratory values, despite adequate medical treatment, a decision was made to introduce haemodialytical therapy in order to remove the drug and therapy reduce the nephrotoxicity. From the results obtained, haemodialysis can therefore be suggested as a useful therapy in rare cases of progressive acute renal failure caused by desferrioxamine.


Asunto(s)
Lesión Renal Aguda/inducido químicamente , Terapia por Quelación/efectos adversos , Deferoxamina/efectos adversos , Bombas de Infusión Implantables , Diálisis Renal , Talasemia beta/complicaciones , Lesión Renal Aguda/terapia , Adulto , Deferoxamina/administración & dosificación , Sobredosis de Droga , Falla de Equipo , Servicios de Atención de Salud a Domicilio , Humanos , Infusiones Intravenosas/instrumentación , Masculino , Talasemia beta/tratamiento farmacológico
17.
Artículo en Inglés | MEDLINE | ID: mdl-8055094

RESUMEN

Dilatative cardiomyopathy is a late complication of Cooley's anemia resulting in severe heart failure resistant to conventional medical treatment. Anemia, iron and fluid overload are the main causes of this disease entity. Four male patients (mean age 22.3 +/- 5.4 years) with Cooley's anemia associated heart failure--4th NYHA and fluid overload > 20% body weight--resistant to medical treatment, underwent isolated ultrafiltration (IU). During 90 minutes of treatment an average of 1750 +/- 850 ml of fluid were removed using AN69S plate membrane. Each patient received an average of 7 IU sessions (range 4-13). Cardiac function was assessed before and after each session with echocardiography, venous cardiac catheterization and impedence cardiography. Transient cardiac improvement was observed after each IU session: left ventricular systolic diameter decreased, as did central venous pressure and pulmonary wedge pressure, whereas cardiac index increased. All patients died of unrelated causes. In conclusion IU treatment in dilatative cardiomyopathy resistant to conventional medical treatment in Cooley's anemia patients produces only transient cardiac improvement, but no improvement in overall survival.


Asunto(s)
Insuficiencia Cardíaca/terapia , Hemofiltración , Talasemia beta/complicaciones , Adulto , Estudios de Evaluación como Asunto , Insuficiencia Cardíaca/etiología , Humanos , Masculino
18.
Kidney Int ; 46(2): 467-70, 1994 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-7967359

RESUMEN

Nineteen transfusion-dependent beta-thalassemia major patients were included in the study. Six of these patients underwent chelation therapy with desferrioxamine by subcutaneous infusion (50 mg/kg/12 hr) and 13 received intravenous infusion (50 mg/kg/6 hr or 100 mg/kg/24 hr). BUN, creatinine, creatinine clearance, beta 2-microglobulin, urinary beta 2-microglobulin and urinary growth hormone excretion were evaluated during desferrioxamine treatment. Thirteen out of nineteen patients presented tubular damage indicated by increased excretion of urinary beta 2-microglobulin. 85% (11 of 13) of these patients showed more serious tubular damage, as demonstrated by concurrent increased urinary growth hormone excretion. Moreover, a positive correlation between urinary growth hormone excretion and urinary beta 2-microglobulin was observed (P < 0.05).


Asunto(s)
Deferoxamina/efectos adversos , Enfermedades Renales/inducido químicamente , Enfermedades Renales/diagnóstico , Talasemia beta/terapia , Administración Cutánea , Adolescente , Adulto , Niño , Preescolar , Deferoxamina/administración & dosificación , Deferoxamina/uso terapéutico , Ensayo de Inmunoadsorción Enzimática , Femenino , Hormona del Crecimiento/orina , Humanos , Ensayo Inmunorradiométrico , Infusiones Intravenosas , Pruebas de Función Renal , Masculino , Microglobulina beta-2/orina , Talasemia beta/orina
19.
Haematologica ; 76(2): 131-4, 1991.
Artículo en Inglés | MEDLINE | ID: mdl-1937171

RESUMEN

BACKGROUND AND METHODS: It is well known that deferoxamine (DFO) treatment in thalassemia major can produce ocular toxicity. In one experience, Visual evoked potentials (VEPS) to pattern reversal were formed to be altered in 4 out of 10 patients under conventional treatment with DFO, before supplementary high-dose i.v. deferoxamine. In all 4 cases the alterations consisted of bilaterally delayed P100 latency, always obtained by stimulation with high spatial frequency (15' checks) and associated in three cases with low spatial frequency (55'). Computerized EEG (cEEG) studies showed a generalized increase of slowing activity. All patients underwent high-dose DFO treatment. RESULTS: At the control performed at the end of treatment in all 4 cases with previous VEP alterations, a further delay in P100 latency was observed bilaterally while two of the six patients, without previous involvement, showed delayed responses when using checks of 15'. The EEG slowing activity was not modified. Three weeks after terminating i.v. DFO therapy, the patients were still under subcutaneous treatment (50 mg/kg/day); a more evident VEP recovery towards the initial values was observed in those patients without initial alterations. No significant changes were found between electrophysiological parameters and serum ferritin levels. CONCLUSIONS: Our results indicate that high-dose DFO therapy in patients with iron overload induces reversible visual impairment without significant changes in brain electrical activity. The employment of VEP in intensive chelation programs in thalassemia major is discussed.


Asunto(s)
Encéfalo/efectos de los fármacos , Terapia por Quelación , Deferoxamina/efectos adversos , Electroencefalografía/efectos de los fármacos , Potenciales Evocados Visuales/efectos de los fármacos , Hemocromatosis/terapia , Hierro , Talasemia/terapia , Adolescente , Adulto , Encéfalo/fisiopatología , Terapia por Quelación/efectos adversos , Niño , Deferoxamina/uso terapéutico , Electrofisiología , Femenino , Ferritinas/análisis , Hemocromatosis/etiología , Humanos , Masculino , Reacción a la Transfusión
20.
Br J Haematol ; 56(1): 79-85, 1984 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-6322833

RESUMEN

Fifty-one subjects originating from Southern Italy and affected by Cooley's anaemia have been studied in order to define the degree of heterogeneity of beta thalassaemia mutations in this high incidence area. Restriction endonuclease mapping has been carried out on genomic DNA by the Southern blot technique both to exclude the existence of gross deletions or rearrangements and to establish the relative frequency of four polymorphic restriction sites (i.e. G gamma and A gamma Hind III, beta Ava II and beta Bam HI) within the gamma delta beta gene region. In 28 subjects unequivocal linkage of the four polymorphic sites has been determined leading to the identification of seven different chromosome haplotypes, six of which had previously been reported associated with specific beta(0) and beta(+) thalassaemia mutations. Globin chain synthesis studies on peripheral blood reticulocytes indicated that subjects carrying the same genotype may behave differently as far as the beta chain production is concerned relative to both the alpha and the non-alpha chains. Thus, beta thalassaemia turns out to be quite heterogeneous even in this limited geographical area. Beta(+) mutations appear to be predominant, particularly those affecting nuclear precursor RNA splicing to mature beta globin mRNA.


Asunto(s)
Globinas/genética , Talasemia/genética , Mapeo Cromosómico , ADN/genética , Enzimas de Restricción del ADN , Frecuencia de los Genes , Ligamiento Genético , Globinas/biosíntesis , Humanos , Italia , Mutación , Polimorfismo Genético , Talasemia/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA